Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899122 | 1.00 | FPR2 (0.56) | FPR2CHRM3CHRM2DRD2DRD4 | |
| SCHEMBL3941523 | 1.00 | FPR2 (0.56) | FPR2CHRM3CHRM2DRD2DRD4 | |
| SCHEMBL13898835 | 0.84 | CHRM3 (0.56) | FPR2CHRM3CHRM2DRD2DRD4 | |
| SCHEMBL13898844 | 0.81 | CHRM3 (0.53) | FPR2CHRM3CHRM2DRD2DRD4 | |
| SCHEMBL6384049 | 0.81 | CHRM3 (0.53) | FPR2CHRM3CHRM2DRD2DRD4 | |
| SCHEMBL3936589 | 0.81 | CHRM3 (0.53) | FPR2CHRM3CHRM2DRD2DRD4 | |
| SCHEMBL13899123 | 0.81 | CHRM3 (0.53) | FPR2CHRM3CHRM2DRD2DRD4 | |
| Bromide SCHEMBL3934084 | 0.79 | CHRM3 (0.51) | FPR2CHRM3CHRM2DRD2DRD4 | |
| Bromide SCHEMBL3931967 | 0.79 | CHRM3 (0.51) | FPR2CHRM3CHRM2DRD2DRD4 | |
| SCHEMBL5633429 | 0.76 | ACHE (0.59) | CHRM3CHRM2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262307-B2 | 1′-benzyl-3-bromo-[1,3′]bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2007-08-28 | — | — | US | claimed |
| EP-1311518-B1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2005-11-02 | — | — | EP | claimed |
| US-20050070722-A1 | 1'-Benzyl-3-bromo-[1,3']bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2005-03-31 | — | — | US | claimed |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG (CH) | 2003-10-16 | — | — | US | claimed |
| US-7511154-B2 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICALS AG (CH) | 2009-03-31 | — | — | US | disclosed |
| US-20080009637-A1 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG | 2008-01-10 | — | — | US | disclosed |
| US-7262307-B2 | 1′-benzyl-3-bromo-[1,3′]bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2007-08-28 | — | — | US | disclosed |
| US-7262307-B2 | 1′-benzyl-3-bromo-[1,3′]bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2007-08-28 | — | — | US | disclosed |
| EP-1311518-B1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| US-20050070722-A1 | 1'-Benzyl-3-bromo-[1,3']bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2005-03-31 | — | — | US | disclosed |
| US-20050070722-A1 | 1'-Benzyl-3-bromo-[1,3']bipyrrolidinyl-2-one | BASILEA PHARMACEUTICA AG (CH) | 2005-03-31 | — | — | US | disclosed |
| US-6828442-B2 | Coupling N-benzyl-3-pyrrolidinamine compound with acyl halide; cyclization in presence of a base; reacting with triphenylphosphine to obtain phosphonium salt; reacting with di-tert. -butyl-dicarbonate under hydrogenation conditions | BASILEA PHARMACEUTICA AG (CH) | 2004-12-07 | — | — | US | disclosed |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | BASILEA PHARMACEUTICA AG (CH) | 2003-10-16 | — | — | US | disclosed |
| EP-1311518-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | Basilea Pharmaceutica AG (CH) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002014332-A1 | PREPARATION OF N-PROTECTED-3-PYRROLIDINE-LACTAM SUBSTITUTED PHOSPHONIUM SALTS | BASILEA PHARMACEUTICA AG (CH) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009637-A1 | Preparation of N-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PNISR, CLK3 | FPR2 3529/4885CHRM3 3106/4885CHRM2 3120/4885 |
| US-20030195364-A1 | Preparation of n-protected-3-pyrrolidine-lactam substituted phosphonium salts | PNKP, PHOSPHO1, PTMS | FPR2 3578/4885CHRM3 3163/4885CHRM2 3132/4885 |
| US-20050070722-A1 | 1'-Benzyl-3-bromo-[1,3']bipyrrolidinyl-2-one | BRD1, BRD4, BET1 | FPR2 1281/4885CHRM3 4394/4885CHRM2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.